RecruitingPhase 1NCT07040930

Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.

Studying NON RARE IN EUROPE: Rheumatoid arthritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Principal Investigator
Jing Zhang, M.D.
Huashan Hospital
Intervention
GenSci120(drug)
Enrollment
30 target
Eligibility
18-55 years · All sexes
Timeline
20252026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07040930 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Rheumatoid arthritis

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Rheumatoid arthritis

← Back to all trials